What is Intercept Pharmaceuticals?
Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative treatments for liver diseases. The company focuses on addressing critical unmet medical needs within hepatology, leveraging specialized expertise in disease mechanisms and drug development. Intercept's strategic approach involves rigorous scientific investigation into the underlying biology of liver conditions to advance a pipeline of investigational medicines. Their efforts aim to provide meaningful therapeutic options for patients suffering from various hepatic conditions globally, supported by capabilities in research, clinical development, and commercialization.
How much funding has Intercept Pharmaceuticals raised?
Intercept Pharmaceuticals has raised a total of $1.5B across 11 funding rounds:
Series B
$25M
Series C
$30M
Stock Offering
$75M
Stock Offering
$61.7M
Stock Offering
$183.3M
Debt
$447.7M
Stock Offering
$250M
Debt
$210.4M
Stock Offering
$200M
Series B (2010): $25M supported by Genextra S.p.A
Series C (2012): $30M featuring Genextra S.p.A and OrbiMed
Stock Issuance/Offering (2012): $75M, investors not publicly disclosed
Stock Issuance/Offering (2013): $61.7M, investors not publicly disclosed
Stock Issuance/Offering (2014): $183.3M, investors not publicly disclosed
Debt (2016): $447.7M, investors not publicly disclosed
Stock Issuance/Offering (2018): $250M featuring Genextra S.p.A and Samsara BioCapital, L.P.
Debt (2019): $210.4M, investors not publicly disclosed
Stock Issuance/Offering (2019): $200M, investors not publicly disclosed
Key Investors in Intercept Pharmaceuticals
Genextra S.p.A
Genextra is a privately owned holding company that invests in early-stage life science companies. The company focuses on identifying innovative research in life sciences and aims to advance novel therapies and technologies through successful business initiatives. Their mission is to foster the development of new therapies and tools by creating companies that support this innovation. Genextra targets clients in the life science sector, particularly those involved in research and development.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development.
Balyasny Asset Management
Balyasny Asset Management is a global investment firm focused on delivering consistent returns for institutional investors. The company uses deep research, advanced technology, and disciplined risk management to identify opportunities across financial markets, including equities, macro strategies, and quantitative trading while fostering a collaborative and performance driven culture.
What's next for Intercept Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment indicate Intercept Pharmaceuticals is in a scaling phase, likely focused on advancing its late-stage clinical pipeline and preparing for potential commercial launches. This capital infusion is expected to fuel further research and development, expand clinical trial operations, and strengthen its market presence. The company's commitment to addressing complex liver diseases positions it for significant impact within the hepatology therapeutic area, with future growth contingent on successful clinical outcomes and regulatory approvals.
See full Intercept Pharmaceuticals company page
